UBS Group’s BioRestorative Therapies BRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$0 Sell
1
-99,831
-100% -$29.2K ﹤0.01% 10474
2026
Q1
$27.2K Buy
+99,832
New +$64.1K ﹤0.01% 7754
2025
Q3
Sell
-3
Closed -$5 10362
2025
Q2
$5 Sell
3
-8,343
-100% -$14.5K ﹤0.01% 10174
2025
Q1
$14.9K Sell
8,346
-7,951
-49% -$15.2K ﹤0.01% 8409
2024
Q4
$23.3K Buy
16,297
+15,604
+2,252% +$24.1K ﹤0.01% 7780
2024
Q3
$1.21K Sell
693
-27,120
-98% -$44.7K ﹤0.01% 8689
2024
Q2
$56.5K Buy
27,813
+26,973
+3,211% +$38.9K ﹤0.01% 6604
2024
Q1
$1.16K Buy
840
+746
+794% +$1.15K ﹤0.01% 8210
2023
Q4
$164 Buy
94
+93
+9,300% +$177 ﹤0.01% 8854
2023
Q3
$2 Sell
1
-3,078
-100% -$7.76K ﹤0.01% 9343
2023
Q2
$13.6K Buy
3,079
+1,484
+93% +$7.1K ﹤0.01% 7037
2023
Q1
$5.42K Buy
1,595
+1,594
+159,400% +$4.89K ﹤0.01% 8041
2022
Q4
$3 Sell
1
-1,566
-100% -$4.88K ﹤0.01% 10634
2022
Q3
$5K Buy
1,567
+1,068
+214% +$3.32K ﹤0.01% 9170
2022
Q2
$1K Buy
499
+498
+49,800% +$2.11K ﹤0.01% 9824
2022
Q1
$0 Sell
1
-303
-100% -$1.31K ﹤0.01% 10276
2021
Q4
$1K Buy
+304
New +$1.74K ﹤0.01% 9956

Other funds holding BRTX

UBS Group's BRTX Position: Q2 2026 in Review

UBS Group reduced its BioRestorative Therapies (BRTX) stake by 100% in Q2 2026, selling an estimated $29.2K and leaving 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #10474.

UBS Group first reported a position in BRTX in Q4 2021 and has held it in 17 quarters since. The position peaked at $56.5K in Q2 2024. 21 funds tracked by Wall St. Rank hold BRTX as of Q2 2026.

  • UBS Group held 1 share of BioRestorative Therapies worth $0 as of Q2 2026.
  • UBS Group sold 99,831 BioRestorative Therapies shares in Q2 2026, an estimated $29.2K.
  • BioRestorative Therapies made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10474 holding.
  • UBS Group first reported a position in BioRestorative Therapies in Q4 2021 and has held it in 17 quarters since.
  • UBS Group's BioRestorative Therapies position peaked at $56.5K in Q2 2024.
  • 21 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.